Furthermore, EGFRm circulating tumor DNA (ct-DNA) clearance on treatment (around cycle 3/4) predicted longer PFS in patients with detectable baseline ctDNA, while nearly half of the patients developed acquired resistance, mainly involving MET, EGFR, and KRAS alterations. Here, KRAS is linked to neoplasm.